KALA - Kala Pharmaceuticals, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Income Statement
Balance Sheet
Cash Flow

Income Statement

All numbers in thousands
Total Revenue---45
Cost of Revenue----
Gross Profit---45
Operating Expenses
Research Development29,29029,00825,02911,382
Selling General and Administrative35,43110,8677,6404,609
Non Recurring----
Total Operating Expenses64,72139,87532,66915,991
Operating Income or Loss-64,721-39,875-32,669-15,946
Income from Continuing Operations
Total Other Income/Expenses Net-2,017-2,336-498-736
Earnings Before Interest and Taxes-64,721-39,875-32,669-15,946
Interest Expense-3,314-1,019-767-604
Income Before Tax-66,738-42,211-33,167-16,682
Income Tax Expense----
Minority Interest----
Net Income From Continuing Ops-66,738-42,211-33,167-16,682
Non-recurring Events
Discontinued Operations----
Extraordinary Items----
Effect Of Accounting Changes----
Other Items----
Net Income
Net Income-66,738-42,211-33,167-16,682
Preferred Stock And Other Adjustments----
Net Income Applicable To Common Shares-66,738-42,211-33,167-16,682